Analytical Data
-
Gene name
HLA-A*11:01&B2M&KRAS G12D(VVVGADGVGK)
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGADGVGK
-
Molecular Weight
51-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the recombinant protein HLA-A*11:01 in conjunction with β2-microglobulin (B2M) and the KRAS G12D mutation (amino acid sequence VVVGADGVGK) is rooted in the quest to enhance cancer immunotherapy. HLA-A*11:01 is a major histocompatibility complex (MHC) class I molecule that plays a crucial role in presenting tumor-derived peptides to CD8+ T cells, thus triggering an immune response. The KRAS G12D mutation is prevalent in various cancers, especially pancreatic and colorectal cancers, and is associated with poor patient prognosis. By engineering the HLA-A*11:01 molecule to present the specific KRAS G12D-derived peptide, researchers aim to elicit a robust and targeted cytotoxic T cell response against cancer cells expressing this mutation. This approach could potentially lead to novel therapeutic strategies, including peptide-based vaccines or adoptive T cell therapies, aimed at improving the immune system’s ability to recognize and eliminate KRAS-driven tumors. Understanding the interactions between HLA-A*11:01, B2M, and the KRAS G12D peptide is critical for optimizing the design of anticancer immunotherapies and could pave the way for personalized treatment options tailored to individual patient profiles. The development of this recombinant protein serves as a vital step in harnessing the immune system to fight against tumors characterized by specific genetic alterations, thus contributing to the advancement of precision medicine in oncology.
